Which act provides financial incentives for pharmaceutical companies to develop medications that treat rare diseases?

Choice A reason: The Department of Health and Human Services oversees public health programs and agencies but does not directly provide financial incentives for rare disease drug development. Choice B reason: The National Organization for Rare Disorders advocates for patients and supports research, but it is not a legislative body and does not enact financial incentive programs. Choice C reason: The Food and Drug Administration regulates drug approval and safety. While it administers the Orphan Drug Act, it is not the source of the legislation itself. Choice D reason: The Orphan Drug Act, passed in 1983, provides financial incentives such as tax credits, grant funding, and market exclusivity to encourage pharmaceutical companies to develop treatments for rare diseases affecting fewer than 200,000 people in the U.S.